Erectile dysfunction in men with cardiovascular disease: the possibility of prevention with Eromax

Abstract

Objective. To analyze research of the problem of occurrence and prevention of erectile dysfunction in men with cardiovascular diseases. Material and methods. Analysis of the literature data reflecting investigations of the problem of erectile dysfunction in men with cardiovascular diseases was carried out. Results and discussion. Erectile dysfunction is a fairly common disease in men. It is manifested by an inability to achieve or maintain an erection, sufficient to have sexual intercourse for more than 3 months. In the Russian Federation, erectile dysfunction occurs in 48.9% of men aged 20–77 years. Erectile dysfunction and cardiovascular disease share common pathogenetic mechanisms. A combination of these pathologies is often seen in the same patient. Age and cardiovascular disease are associated with an increased risk of erectile dysfunction. Conclusion. The Russian drug Eromax (Parafarm company) is able to increase sexual desire, improve the duration of an erection and mood, stabilize the vegetative system and may be recommended for the prevention of erectile dysfunction and for improving the quality in men with cardiovascular diseases, taking into consideration the existing comorbid pathology and an individual approach to each patient.